公司資料
iRadimed 股價、新聞與催化劑
- 股票代碼:
- IRMD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
88.02 USD (+1.23%)
收盤價
最後更新: 2026年8月17日
1.15B USD
市值
股價為何變動
As of Aug 17, 2026, IRMD closed up 1.23% at $88.02. No new same-company headline was identified in the current news window.
公司概覽
MRI-Compatible Device Specialist
IRADIMED is a medical device company focused on products designed for use during magnetic resonance imaging procedures. Its core portfolio includes non-magnetic IV infusion pump systems and patient vital signs monitoring systems, along with related accessories, disposables, and services. This gives the company a narrow but defensible position in a clinical environment where standard equipment can create safety and workflow challenges.
Infusion Pump Platform Transition
The company's near-term operating story is centered on the launch of the 3870 MR IV pump, a next-generation platform that is replacing revenue from the older 3860 pump. Initial shipments began during the second quarter of 2026, with management describing the period as the first sizable production ramp for the new pump. Customer demand appears to be shifting toward higher-channel configurations, with more than 70% of new pump orders placed for the four-pump "quad stack" setup.
Monitoring Systems and Domestic Base
IRADIMED also sells MRI-compatible patient monitoring systems, and domestic monitor unit bookings reached a record level during the quarter. Domestic sales remain the majority of revenue, giving the business strong exposure to U.S. hospital MRI-suite capital and workflow spending.
Strategic Position
IRADIMED is best understood as a focused MRI safety and workflow company rather than a broad hospital equipment supplier. Its differentiation comes from designing devices specifically for the MRI environment, where non-magnetic design, regulatory clearance, and clinical reliability matter. Near-term performance depends on the 3870 pump ramp, monitor demand, manufacturing efficiency, and continued hospital adoption of MRI-compatible systems.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。